Laquinimod, a quinoline-3-carboxamide, induces type II myeloid cells that modulate central nervous system autoimmunity. by Schulze-Topphoff, Ulf et al.
UCSF
UC San Francisco Previously Published Works
Title
Laquinimod, a quinoline-3-carboxamide, induces type II myeloid cells that modulate central 
nervous system autoimmunity.
Permalink
https://escholarship.org/uc/item/4q005137
Journal
PloS one, 7(3)
ISSN
1932-6203
Authors
Schulze-Topphoff, Ulf
Shetty, Aparna
Varrin-Doyer, Michel
et al.
Publication Date
2012
DOI
10.1371/journal.pone.0033797
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
Laquinimod, a Quinoline-3-Carboxamide, Induces Type II
Myeloid Cells That Modulate Central Nervous System
Autoimmunity
Ulf Schulze-Topphoff1., Aparna Shetty1., Michel Varrin-Doyer1, Nicolas Molnarfi1¤, Sharon A. Sagan1,
Raymond A. Sobel2, Patricia A. Nelson1, Scott S. Zamvil1*
1Department of Neurology and Program in Immunology, University of California, San Francisco, San Francisco, California, United States of America, 2Department of
Pathology, Stanford University, Stanford, California, United States of America
Abstract
Laquinimod is a novel oral drug that is currently being evaluated for the treatment of relapsing-remitting (RR) multiple
sclerosis (MS). Using the animal model for multiple sclerosis, experimental autoimmune encephalomyelitis (EAE), we
examined how laquinimod promotes immune modulation. Oral laquinimod treatment reversed established RR-EAE and was
associated with reduced central nervous system (CNS) inflammation, decreased Th1 and Th17 responses, and an increase in
regulatory T cells (Treg). In vivo laquinimod treatment inhibited donor myelin-specific T cells from transferring EAE to naive
recipient mice. In vivo laquinimod treatment altered subpopulations of myeloid antigen presenting cells (APC) that included
a decrease in CD11c+CD11b+CD4+ dendritic cells (DC) and an elevation of CD11bhiGr1hi monocytes. CD11b+ cells from these
mice exhibited an anti-inflammatory type II phenotype characterized by reduced STAT1 phosphorylation, decreased
production of IL-6, IL-12/23 and TNF, and increased IL-10. In adoptive transfer, donor type II monocytes from laquinimod-
treated mice suppressed clinical and histologic disease in recipients with established EAE. As effects were observed in both
APC and T cell compartments, we examined whether T cell immune modulation occurred as a direct effect of laquinimod on
T cells, or as a consequence of altered APC function. Inhibition of Th1 and Th17 differentiation was observed only when type
II monocytes or DC from laquinimod-treated mice were used as APC, regardless of whether myelin-specific T cells were
obtained from laquinimod-treated or untreated mice. Thus, laquinimod modulates adaptive T cell immune responses via its
effects on cells of the innate immune system, and may not influence T cells directly.
Citation: Schulze-Topphoff U, Shetty A, Varrin-Doyer M, Molnarfi N, Sagan SA, et al. (2012) Laquinimod, a Quinoline-3-Carboxamide, Induces Type II Myeloid Cells
hat Modulate Central Nervous System Autoimmunity. PLoS ONE 7(3): e33797. doi:10.1371/journal.pone.0033797
Editor: Martin Sebastian Weber, Klinikum rechts der Isar der Technischen Universitaet Muenchen, Germany
Received December 13, 2011; Accepted February 17, 2012; Published March 30, 2012
Copyright:  2012 Schulze-Topphoff et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which
permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: Support for this work was provided to SSZ by the National Institutes of Health (NIH) (RO1 AI073737 and RO1 NS063008), the National Multiple Sclerosis
Society (NMSS, RG 4124), Teva Pharmaceuticals, Inc. and the Maisin Foundation. US-T is a fellow of the Deutsche Forschungsgemeinschaft (DFG; SCHU 2587/1-1).
The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have read the journal’s policy and have the following conflicts: Support for this work was provided to SSZ by Teva
Pharmaceuticals, Inc.. SSZ has received personal compensation serving as a consultant or serving on data safety monitoring boards for Biogen-Idec, Teva, EMD
Merck Serono, Genzyme, Novartis, Eli Lilly and Bayhill Therapeutics. This does not alter the authors’ adherence to all PLoS ONE policies on sharing data and
materials.
* E-mail: zamvil@ucsf.neuroimmunol.org
. These authors contributed equally to this work.
¤ Current address: Department of Pathology and Immunology, University of Geneva, Geneva, Switzerland
Introduction
Laquinimod (N-ethyl-N-phenyl-5-chloro-1, 2-dihydroxy-1-
methyl-2-oxo-quinoline-3-carboxamide) is a novel oral agent with
immunomodulatory properties that is currently under evaluation
for treatment of relapsing-remitting (RR) multiple sclerosis (MS)
and other autoimmune diseases [1–3]. Laquinimod is structurally
related to roquinimex (linomide), which demonstrated efficacy in
MS [4], although its development was halted after unanticipated
serious adverse events occurred in a phase III trial [5]. In
screening a large number of chemically modified quinoline-3-
carboxamides, laquinimod was discovered to have less toxicity and
greater efficacy than linomide in the MS model, experimental
autoimmune encephalomyelitis (EAE) [6]. Laquinimod has since
shown efficacy in phase II and phase III MS clinical trials, without
evident immunosuppression or significant toxicities [1,2,7].
Studies in EAE indicate that laquinimod can promote immune
modulation and neuroprotection [8,9]. Laquinimod inhibited
development of EAE [9–11] and suppressed production of
proinflammatory cytokines [8,9,12]. However, those studies did
not address the mechanisms responsible for alteration of T cell
responses. It is possible that laquinimod could act directly on T
cells, or modulate T cell responses through its effects on accessory
cells. In this regard, it is now understood that some medications
currently used in MS treatment exert effects through antigen
presenting cells (APC) [13,14], which then contribute to T cell
immune modulation [13,15].
In this study, we investigated laquinimod’s mechanism of action
for immune modulation. Oral laquinimod treatment initiated
during remission prevented further relapses and reduced central
nervous system (CNS) inflammation. In vivo laquinimod treatment
was associated with reduced proinflammatory Th1 and Th17
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responses, elevation of CD4+CD25+Foxp3+ regulatory T cells
(Treg), and alterations in dendritic cells (DC) and monocyte
subpopulations. These myeloid cells exhibited an anti-inflamma-
tory (type II) cytokine and signaling profile [16,17]. When used as
APC, they promoted development of Treg and inhibited
differentiation of proinflammatory T cells, regardless of whether
or not T cells were exposed to laquinimod. Our results
demonstrate that laquinimod modulates T cell immune responses
through a direct effect on myeloid APC.
Results
Laquinimod reverses EAE and inhibits pathogenic T cell
immune responses
Laquinimod was tested in prevention of chronic EAE in two
mouse strains, DBA/1 (H-2q) and C57BL/6 (H-2b). When
immunized with recombinant MOG 1–125, DBA/1 mice are
known to develop a severe disease course [18]. As shown in
Figure 1A, oral laquinimod treatment prevented development of
EAE in DBA/1 mice. Similarly, oral laquinimod treatment
prevented induction of MOG p35-55-induced EAE in C57BL/6
mice.(Fig. 1B). Very few infiltrating CD4+ T cells were detected in
the CNS of laquinimod-treated mice, whereas abundant CNS
infiltration of CD4+ Th1, Th17 and GM-CSF expressing cells
were detected in vehicle-treated mice (Fig. 1C, p,0.01). Recent
studies demonstrated the important role of GM-CSF on the
encephalitogenicity of Th1 and Th17 cells in EAE [19,20]. To
determine whether laquinimod prevents EAE by modulating
peripheral T cell immune responses important for the develop-
ment of the disease, CD4+ splenocytes from mice treated with
laquinimod or vehicle were analyzed for their inflammatory
profile. Preventive treatment with laquinimod significantly de-
creased the number of IFN-c and IL-17 producing cells (Fig. 1D,
p,0.01). In addition to a decrease in Th1 and Th17 responses, we
observed a corresponding increase in CD4+CD25+Foxp3-express-
ing regulatory T cells (Treg, Fig. 1D, p,0.01). As we observed that
laquinimod treatment inhibited proinflammatory T cell responses,
we addressed whether it altered the encephalitogenic potential of
myelin-specific T cells when transferred to naı¨ve mice. As shown
in Figure 1E, PLP-specific T cells from laquinimod-treated mice,
which produced reduced quantities of proinflammatory cytokines,
were less encephalitogenic than T cells from vehicle-treated mice
(Fig. 1E, Fig. S1).
It was demonstrated that laquinimod treatment prior to, or at
the time of onset of clinical signs, suppressed EAE development in
C57BL/6 mice immunized with MOG p35-55 [9]. In a study of
EAE induced by myelin basic protein in B10.RIII mice, it was
observed that laquinimod treatment after onset, but before peak of
clinical disease, prevented subsequent relapses [21]. We examined
whether laquinimod could reverse established RR-EAE in SJL/J
mice. When oral laquinimod treatment was initiated during
remission after the first exacerbation, it prevented subsequent
relapses (Fig. 2A). Histological analysis of these mice revealed a
significant reduction in CNS inflammatory lesions (Fig. 2B).
Laquinimod mediates T cell immune responses via a
direct effect on APC function
We next addressed whether laquinimod mediated immune
modulation by acting on T cells directly or through alteration of
APC function. Purified CD11b+ cells from laquinimod- or vehicle-
treated mice were tested as APC for stimulation of naı¨ve MOG
p35-55-specific (2D2) T cells under Th1- or Th17-polarizing
conditions. In a reciprocal manner, we examined how purified
naı¨ve MOG p35-55-specific T cells from vehicle- or laquinimod-
treated 2D2 mice responded to CD11b+ APC from untreated
mice. CD11b+ APC from laquinimod-treated mice, but not from
untreated mice, inhibited the development of Th1 (Fig. 2C) and
Th17 cells (Fig. 2D). In contrast, no difference in Th1 and Th17
polarization was observed when purified MOG-specific T cells
from laquinimod-treated mice were cultured with untreated
CD11b+ APC (Fig. 2C, 2D). In line with these findings,
proliferation of 2D2 T cells was reduced when CD11b+ cells
from laquinimod-treated mice were used as APC, although no
effect on T cell proliferation was observed when 2D2 T cells from
laquinimod-treated mice were cultured with vehicle-treated
CD11b+ cells or activated by anti-CD3/anti-CD28 in the absence
of APC (Fig. S2).
As our data indicated that laquinimod-mediated T cell immune
modulation was driven through its influence on APC, we
investigated how oral laquinimod treatment affected individual
subsets of myeloid APC. First, we examined classical CD11chigh
dendritic cells (cDC), including CD8+ cDC (CD8a+ CD42
CD11b2) and CD4+ cDC (CD4+ CD82 CD11b+). A significant
decrease of CD4+ cDC, which are particularly potent APC among
subpopulations of DC [22,23], was observed after seven days of
laquinimod treatment. In contrast, we did not detect significant
changes in the frequency of CD8+ cDC (Fig. S3). A similar pattern
of DC subpopulations and T cells was observed in laquinimod-
treated mice that had been immunized for EAE induction (data
not shown). Further, we did not observe alterations in the
frequencies of CD4+ or CD8+ T cells, showing that laquinimod
treatment alone did not alter T cell homeostasis in naı¨ve mice
(Fig. 3A, Fig. S3). Interestingly, laquinimod treatment also did not
alter proliferative responses in rats immunized with the enceph-
alitogenic peptide, MBP p68-86 [24].
CD11b+Gr1+ cells, known as myeloid-derived suppressor cells,
can exhibit regulatory function [25–27]. Upon laquinimod
treatment, we observed a significant increase in frequency of
CD11b+Gr1+hi cells in naı¨ve mice (Fig. 3B). As oral laquinimod
treatment induced changes in both CD11c+ and CD11b+ APC
subsets, we evaluated whether alteration of APC function was
unique, or common to both subpopulations. Here, we evaluated
whole splenic CD11b+, CD11b+CD11c2 and CD11c+ cells from
laquinimod-treated mice. Under either proinflammatory-polariz-
ing (Fig. 3C–E) or non-polarizing conditions (Fig. 3F), each of
these myeloid APC subpopulations inhibited differentiation of Th1
and Th17 cells (Fig. 3C–F). An expansion in frequency of Treg
was observed when we examined cultures using CD11b+ cells as
APC (Fig. 3F). Our results demonstrate that T cell immune
modulation induced by oral laquinimod treatment is not limited to
its effects on one specific myeloid APC subset.
Laquinimod induces type II monocytes and DC
T cell immune modulation in glatiramer acetate (GA) therapy of
MS and EAE is associated with expansion of anti-inflammatory
type II (M2) monocytes that produce less proinflammatory
cytokines and elevated levels of anti-inflammatory cytokines
[16,17,28]. As myeloid APC in laquinimod treatment directed T
cell immune modulation, we evaluated the cytokines produced by
monocytes and DC. As shown in Figure 4A, both
CD11b+CD11c2 monocytes and CD11c+ DC from laquinimod-
treated naive (unimmunized) mice exhibited a type II phenotype,
characterized by reduced cellular production of proinflammatory-
polarizing cytokines IL-6, IL-12/23 (p40) and TNF, and a
corresponding increase in anti-inflammatory IL-10. This type II
cytokine profile was also detected in myeloid APC subsets isolated
from laquinimod-treated mice immunized with MOG p35-55 (Fig.
S4). We examined if laquinimod treatment alone influences
Laquinimod in CNS Autoimmunity
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expression of MHC II, CD40, CD80, CD86 and PD-L1, an
inhibitory costimulatory molecule. Laquinimod treatment of naive
mice was consistently associated with a small, but significant,
reduction in CD80 (Fig. 4B). Our results clearly demonstrate that
oral laquinimod treatment promotes development of both type II
monocytes and type II DC, which are capable of inhibiting
proinflammatory myelin-specific T cell responses.
As laquinimod inhibited proinflammatory cytokine production
by monocytes and DC, we examined whether in vivo laquinimod
treatment altered key signaling pathways that participate in
expression of these molecules. Activation of the Janus kinase
signal transducer and activator of transcription (JAK-STAT)
pathway is required for expression of several proinflammatory
cytokines of APC, thus influencing T-cell differentiation [29]. As
shown in Figure 4C, LPS-induced STAT1 phosphorylation
(activation) was reduced in CD11b+ monocytes isolated from
laquinimod-treated mice. In contrast, in vivo laquinimod treat-
ment did not alter phosphorylation of p38 mitogen-activated
protein (MAP) kinase, representing another signaling cascade
involved in stress responses. Thus, our data indicate that in vivo
laquinimod treatment alters activation of select signaling pathways
in myeloid type II APC.
In order to investigate whether laquinimod-induced type II
myeloid APC could modulate clinical responses in vivo, we
isolated type II CD11b+ monocytes from laquinimod-treated mice
and adoptively transferred them into recipient mice with
established EAE. These type II CD11b+ monocytes ameliorated
clinical (Fig. 4D) and histological signs (Fig. 4E) of EAE in
recipient mice.
Discussion
In this report, we have observed that oral laquinimod treatment
can prevent or reverse established EAE. In vivo laquinimod
treatment was associated with alterations in myeloid APC
subpopulations that included a reduction in CD4+ cDC, a potent
DC subpopulation. We have shown that laquinimod treatment
promoted development of anti-inflammatory type II monocytes
and DC, reminiscent of our previous work demonstrating that in
vivo treatment of mice with glatiramer acetate (GA, copolymer-1,
CopaxoneH), an approved therapy for RRMS [30], induced
Figure 1. Laquinimod prevents EAE and decreases encephalitogenicity of T cells. DBA/1 (A) mice and C57BL/6 mice (B) were treated daily
with laquinimod (25 mg/kg, n = 6/group) or vehicle (water, n = 6/group) starting from the day of immunization with rMOG 1-125 (DBA/1) or MOG
p35-55 (C57BL/6). Fourteen days after immunization, CNS infiltrating cells (C) and spleen cells (D) from C57BL/6 mice treated with laquinimod or
vehicle were evaluated for secretion of IFN-c, IL-17, GM-CSF and for expression of CD25 and Foxp3 by CD4+ cells. Representative FACS staining is
shown including quantification (n = 4–5 mice per group). (E) Laquinimod decreases pathogenic potential of T cells. Splenocytes and lymph node cells
were isolated from PLP-immunized mice treated with laquinimod or vehicle. Cells were restimulated in vitro, and 107 cells were transferred into naı¨ve
SJL/J recipients (n = 5/group). Data are representative of two independent experiments. For EAE disease course, mean disease score 6 s.e.m. are
displayed; for other experiments mean 6 s.d. *P,0.05, **P,0.01, Mann-Whitney U test.
doi:10.1371/journal.pone.0033797.g001
Laquinimod in CNS Autoimmunity
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differentiation of anti-inflammatory type II monocytes [17].
Laquinimod did not alter numbers of CD4+ T cells. In a previous
study, it was observed that laquinimod treatment reduced
secretion of IFN-c and IL-17 [9]. Here, we have demonstrated
that oral laquinimod administration in EAE was associated with
anti-inflammatory T cell polarization as demonstrated by
reductions in frequencies of proinflammatory Th1 and Th17 cells
in vivo, and an increase in Treg. By studying how in vivo
laquinimod treatment influenced individual populations of mye-
loid APC or naive myelin-specific T cells, we demonstrated that T
cell immune modulation was linked to induction of type II myeloid
APC, but not from its effects on T cells alone. Thus, at physiologic
levels achieved by in vivo treatment, laquinimod impacts APC, but
may not influence T cells directly.
In general, CD4+ and CD8+ T cells, which express antigen-
specific a/b+ T cell receptors, recognize peptide fragments of
processed proteins only in association with polymorphic MHC
molecules on APC [31]. In this regard, GA, which is a
polypeptide-based therapy, provides antigenic determinants and
leads to expansion of GA-reactive T cells that can be identified in
therapy of MS [32–34] or EAE [17,35,36]. The requirement for
MHC II on GA-induced type II monocytes was discovered at the
time adoptive transfer of monocytes was first developed as an
experimental paradigm to study how therapeutics can influence
APC-T cell interaction in vivo [17]. In this regard, GA-induced
type II monocytes from wild-type mice, but not from mice
selectively deficient in MHC II, induced T cell immune
modulation (i.e. expansion of Treg and Th2 cells) and reversed
EAE in recipient mice. However, as a synthetic heterocyclic
molecule, laquinimod itself is unlikely to serve as a target for T cell
recognition. Use of the EAE model permits investigators to
characterize how laquinimod can alter T cell responses that are
elicited by direct immunization with myelin peptides or proteins, a
situation not encountered in MS, a naturally occurring disease.
Evaluating whether laquinimod treatment of MS modulates T cell
function in the absence of active antigenic stimulation may be
Figure 2. Laquinimod reverses RR-EAE and inhibits inflammatory T cell responses via a direct effect on myeloid APC. (A) Daily oral
laquinimod treatment reverses relapsing remitting EAE. SJL/J mice were immunized with PLP p139-151 and treated with laquinimod or vehicle (n = 9)
at the remission phase (arrow points to the start of the treatment). (B) Lesion quantification showed reduced total number of meningeal and
parenchymal inflammatory foci in SJL/J mice treated with laquinimod after first exacerbation of the disease. Representative Luxol fast blue-H&E
staining of the cerebellum is shown. (C, D) Laquinimod-treated myeloid APC inhibit differentiation of naive T cells into Th1 and Th17 cells. Whole
splenic in vivo laquinimod-treated or untreated CD11b+ cells were used as APC in co-culture with untreated naive (CD4+CD442CD62L+) T cells from
MOG p35-55 TCR-transgenic mice (2D2). Conversely, naive T cells were isolated from laquinimod- or vehicle-treated 2D2 mice and cultured with
purified vehicle-treated CD11b+ cells and Ag (MOG p35-55). Polarization of naı¨ve T cells into Th1 lineage was induced by IL-12 (C) and polarization
into Th17 lineage was induced by IL-23, IL-6 and TGF-b (D). Intracellular cytokine staining for IFN-c and IL-17 after three days in culture is shown. For
all experiments, data shown are representative of two independent experiments. For EAE disease course and other experiments, mean disease score
and mean 6 s.e.m. are displayed; *P,0.05, Mann-Whitney U test.
doi:10.1371/journal.pone.0033797.g002
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Figure 3. Laquinimod alters myeloid APC subsets and inhibits Th1 and Th17 polarization of myelin-specific T cells. All experiments
were conducted with myeloid-APC purified (purity $95%) by MACS sorting from mice treated with laquinimod or vehicle for ten days. (A) DC were
isolated from the spleen and defined as CD11chigh. Percentages of splenic CD11chigh CD4+ cDC (CD4+CD11b+) from laquinimod-treated or vehicle-
treated mice (n = 4), and percentage of total splenic CD4+ cells from laquinimod- and vehicle-treated mice (n = 5) are shown. (B) Splenic and blood
CD11b+ cells were stained for Gr1. Relative percentages of CD11b+Gr1hi (arrow points to Gr1hi cells) out of total splenic and blood CD11b+ cells from
mice treated with laquinimod (dark grey bar) or vehicle (white bar) is shown (n = 4). (C–E) Purified splenic CD11b+, CD11b+CD11c2 (C, D) or CD11c+ (E)
cells were used as APC in co-culture with naı¨ve CD4+ 2D2 T cells and Ag (MOG p35-55). Th1 and Th17 differentiation were induced as described
Laquinimod in CNS Autoimmunity
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more challenging. Our observations that in vivo laquinimod
treatment of unimmunized mice modified expression of myeloid
subpopulations and APC function should focus attention on
exploring the mechanism of action of laquinimod in MS therapy
on cells of the innate immune system. Our demonstration that
laquinimod has a principle effect on innate immunity provides
above. Intracellular cytokine staining shows the percentage of IL-17 and IFN-c after 3 days in culture (gate). (F) Purified splenic CD11b+CD11c2 or
CD11c+ cells were used as APC in co-culture with naı¨ve CD4+ 2D2 T cells under non-polarizing conditions. FACS analyses after four days in culture for
IL-17 and IFN-c and for Foxp3 by CD4+ cells is shown. Data shown as mean 6 s.e.m. are representative of at least two independent experiments;
*P,0.05, Mann-Whitney U test.
doi:10.1371/journal.pone.0033797.g003
Figure 4. Laquinimod-induced type II (M2) monocytes reverse established EAE. Laquinimod-induced anti-inflammatory cytokine shift in
CD11b+CD11c2 and CD11c+ cells. (A) FACS analysis of intracellular production of TNF, IL12/23p40, IL-6 and IL-10 by CD11b+CD11c2 and CD11c+ cells
isolated from spleens of naive (unimmunized) mice treated with laquinimod or vehicle. (B) Cell surface FACS analysis of MHC II, proinflammatory and
inhibitory costimulatory molecules on CD11b+CD11c2 cells. (C) In vivo laquinimod treatment affects signaling pathways that participate in
proinflammatory cytokine production. Protein extracts were isolated from peritoneal macrophages of naı¨ve C57BL/6 mice treated with laquinimod or
vehicle and stimulated with LPS for various time points. Phosphorylated (P) STAT1, (P) p38-MAPK, Pan-STAT1 and Pan-p38-MAPK were detected by
Western blot analysis. (D) CD11b+ cells from laquinimod-treated donor mice reversed established EAE. 56106 purified splenic CD11b+ cells from mice
treated with laquinimod or vehicle were injected i.v. into recipient C57BL/6 mice immunized with MOG p35–55 after they developed a disease grade
of 2 (black arrow indicates time point of adoptive transfer, (n = 5/group). (E) Quantification showed reduced total number of inflammatory foci after
adoptive transfer of in vivo laquinimod treated CD11b+ cells into C57BL/6 mice immunized with MOG p35-55. Data shown in panels above are
representative of three independent experiments. For EAE disease course, mean disease score 6 s.e.m. are displayed; *P,0.05, **P,0.01 Mann-
Whitney U test.
doi:10.1371/journal.pone.0033797.g004
Laquinimod in CNS Autoimmunity
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mechanistic insight relevant to results from the two recent phase
III clinical trials in RRMS that tested laquinimod (0.6 mg daily)
and indicated that dose provided a more pronounced effect on
disability progression than relapse rate reduction [37,38]. Further,
our findings also suggest that laquinimod could be beneficial in
secondary progressive MS, a phase that involves chronic
inflammation and neurodegeneration that is thought to be driven
by innate immunity [39].
A recent study evaluated the potential role of brain-derived
neurotrophic factor (BDNF) in laquinimod treatment [40]. A
small, but significant increase in serum BDNF levels was detected
in laquinimod-treated MS patients. These authors also evaluated
the role of BDNF in laquinimod treatment of EAE. It is known
that BDNF-deficient mice develop more severe chronic EAE [41].
They demonstrated that monocytes from laquinimod-treated
donor wild-type mice, but not monocytes from laquinimod-treated
BDNF-deficient mice or from untreated wild-type mice, amelio-
rated EAE in recipient mice. The authors concluded that the
effects of laquinimod on monocytes are BDNF-dependent.
However, they did not transfer untreated BDNF-deficient
monocytes, and therefore did not distinguish the influence of the
production, or the absence, of BDNF alone on monocyte function
independent of laquinimod treatment. In order to attribute the
effect of laquinimod to BDNF production by monocytes using this
experimental approach, it is advantageous to not only compare
laquinimod-treated and untreated wild-type monocytes to laqui-
nimod-treated BDNF-deficient monocytes, but to simultaneously
compare the adoptive transfer of untreated BDNF-deficient
monocytes to both untreated wild-type monocytes and to
laquinimod-treated BDNF-deficient monocytes.
In this investigation, we have identified cellular mechanisms
that contribute to immune modulation by laquinimod, focusing on
the interaction of myeloid APC and T cells. Type II monocyte
differentiation was associated with reduced production of proin-
flammatory IL-6, IL-12/IL-23 (p40) and TNF, and increased
production of anti-inflammatory IL-10. It is important to
characterize the molecular pathway(s) utilized by laquinimod for
this type II cytokine profile. Laquinimod is not known to have a
well-defined target, although some in vitro data suggest that
quinoline-3-carboxamides bind S100A9, a calcium binding
protein [42] that influences cell signaling. Other results indicate
that this class of molecules may alter NF-kB signaling [43]. We
have begun evaluating the signaling events contributing to type II
APC differentiation in monocytes/macrophages isolated from
laquinimod-treated mice. First, we focused on activation of
STAT1, a transcription factor that participates in expression of
several proinflammatory cytokines [44,45]. Laquinimod treatment
suppressed inducible STAT1, but did not alter activation of p38
MAPK, another signaling pathway involved in expression of
proinflammatory cytokines that can be regulated independently or
coordinately with STAT1 [46]. Interestingly, inhibition of STAT1
and p38 MAPK signaling was observed in development of type II
monocytes by GA [17] (N. Molnarfi and S.S. Zamvil, unpub-
lished), suggesting that the signaling events modulated by GA and
laquinimod during type II APC differentiation are not the same.
Our observations represent only the initial steps in understanding
how laquinimod influences intracellular signaling pathways in type
II myeloid cell differentiation. Although we used both in vivo and
ex vivo analyses to evaluate type II myeloid cells, laquinimod was
only administered in vivo, which we believe more closely reflects
the physiology of laquinimod treatment in MS. In contrast with
previous studies [9,11,21,40], we evaluated APC-T cell interac-
tion, the interface between innate and adaptive immunity,
primarily by in vivo laquinimod treatment in the absence of
peptide immunization, and therefore obviating concern of
adjuvant. Our findings in this report support evaluation of type
II myeloid cells in laquinimod treatment of MS patients.
Materials and Methods
Mice
C57BL/6, DBA/1 and SJL/J female mice, 5 to 8 weeks of age,
were purchased from Jackson Laboratories (Bar Harbor, MN,
USA). MOG p35–55–specific TCR transgenic 2D2 mice were
provided by V.K. Kuchroo (Harvard Medical School, Boston,
MA).
Ethics Statement
The experimental protocol adheres to guidelines for animal use
in research set by the National Institutes of Health and was
approved by the Office of Research, University of California San
Francisco (UCSF) Institutional Animal Care and Use Committee
(IACUC Approval AN081032-03B).
Peptides
Mouse MOG p35-55 (MEVGWYRSPFSRVVHLYRNGK)
and mouse PLP p139-151 (HSLAKWLGHPDKF) were synthe-
sized by Auspep (Parkville, Australia). Recombinant rat MOG
(rMOG 1-125) was synthesized by AnaSpec (Fremont, CA).
EAE Induction
Seven to 10-week-old female C57BL/6, DBA/1 or SJL/J mice
were injected subcutaneously with 50 mg MOG p35-55, 50 mg
rMOG or 100 mg PLP p139-151, respectively, in complete
Freund’s adjuvant (DIFCO Laboratories, Detroit, MI). After
immunization and 2 days later, mice received 200 ng (C57BL/6)
or 100 ng (SJL/J) pertussis toxin intraperitoneally (i.p.). For
adoptive transfer, donor SJL/J mice were immunized as described
above and treated daily with laquinimod or vehicle. 10 days later,
cells from draining lymph nodes and spleen were isolated, re-
stimulated for 48 h (20 mg/ml PLP p139-151), and injected i.p.
into naive SJL/J recipients (107 cells per mouse). Animals were
observed daily and clinical scores were assessed as follows: 0, no
signs; 1, decreased tail tone; 2, mild monoparesis or paraparesis; 3,
severe paraparesis; 4, paraplegia and/or quadraparesis; and 5,
moribund or death. All experiments were carried out in
accordance with guidelines prescribed by the Institutional Animal
Care and Use Committee at the University of California, San
Francisco.
Laquinimod treatment
Laquinimod (TEVA Pharmaceuticals Industries, Ltd (Israel))
was dissolved in purified water and administered daily (25 mg/kg)
by oral gavage. This dose was chosen as it was previously observed
that lower doses were less effective [9]. Treatment started at the
day of EAE induction or after first disease exacerbation. Control
mice received a similar volume of vehicle (water) daily [42]. In
other experiments (e.g., monocyte transfer, cytokine analysis, in
vitro APC-T cell assays), mice were treated for 10 days with
laquinimod or vehicle before isolation of specific cell subsets.
Generation of Th1 and Th17 cells
CD4+CD62L+CD44+ naı¨ve T cells were magnetically sorted
from TCR-transgenic 2D2 mice (purity greater than 96%) using
magnetic beads (Miltenyi Biotec, Auburn, CA) and stimulated with
MOG p35-55 (20 mg/ml) in the presence of antigen-presenting
cells (APC, e.g., MACS-sorted CD11b+, CD11c+ cells) at a T cell/
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APC ratio of 1:5. Th17 differentiation was induced by addition of
3 ng/ml TGF-b, 20 ng/ml IL-23, 20 ng/ml IL-6 (R&D Systems,
Minneapolis, MN). For Th1 cells, 10 ng/ml IL-12 (R&D) were
added. Cells were harvested between days 3 and 4, and cytokine
production was analyzed using a FACS Canto flow cytometer
(BD, San Jose, CA).
Monocyte isolation and co-culture with naı¨ve T cells
Splenic CD11b+ and CD11c+ cells were separated from
laquinimod or vehicle-treated mice using magnetic beads
(Miltenyi). We evaluated monocyte and dendritic cell preparations
for expression of CD11b, CD11c, B220, CD3 (BD Pharmingen,
San Diego, CA). Purity of monocytes and dendritic cells used as
APC was routinely greater than 95%. CD11b+, CD11b+CD11c2
or CD11c+ APC were co-cultured with T cells from 2D2
transgenic mice and their respective antigen for 3 days at a ratio
of 25:1.
T cell proliferation
Purified CD11b+ cells from laquinimod- or vehicle-treated mice
were cultured with naı¨ve CD4+ cells isolated from laquinimod- or
vehicle-treated 2D2 mice and antigen (MOG p35-55, 20 mg/ml).
Cells were cultured in 96-well microtitre plates at a concentration
of 0.256106 cells/ml. Culture medium consisted of RPMI 1640
supplemented with L-glutamine (2 mM), sodium pyruvate
(1 mM), penicillin (100 U/ml), streptomycin (0.1 mg/ml), 2-
mercaptoethanol (561025 M) and 10% (v/v) fetal bovine serum.
Cells were incubated for 48 h and pulsed for 18 h with 1 mCi per
well of [3H]-thymidine before harvesting.
Adoptive transfer of monocytes
Monocytes were isolated from the spleens of 8–10-week-old
mice treated with laquinimod or vehicle for 10 days. Monocytes
were enriched by magnetic cell sorting using CD11b+ magnetic
beads (Miltenyi), resulting in a general purity of at least 95%.
Recipient C57BL/6 mice were immunized with MOG p35–55,
randomized at EAE score 2 and injected intravenously (i.v.) with
56106 laquinimod- or vehicle-treated monocytes.
Isolation of CNS infiltrating mononuclear cells
Isolation of CNS infiltrating cells was performed as previously
described [47]. Briefly, mice were perfused using PBS. CNS tissue
was manually cut into small pieces and incubated for 20 min in
Hank’s Buffered Saline Solution containing collagenase. Homog-
enate was resuspended in 30% Percoll (Sigma) and underlain with
70% Percoll and centrifuged for 30 min. Cells were harvested
from the resulting interface.
Histopathology
Brains and spinal cords of mice were fixed in 10% neutral-
buffered formalin, sectioned and stained with Luxol fast blue (LFB)
and hematoxylin and eosin (H&E). Meningeal and parenchymal
inflammatory lesions and areas of demyelination were quantified
as previously described [48,49].
Isolation of peritoneal macrophages
C57BL/6 mice were treated for 10 days with laquinimod or
vehicle. On day 7 of treatment, mice received i.p. injection of 1 ml
thioglycollate (Becton Dickinson). Three days later, macrophages
were harvested from mice by peritoneal lavage. Peritoneal
macrophages were plated on Petri dishes in Dulbecco’s modified
Eagle’s medium (supplemented with 10% heat-inactivated fetal
bovine serum) for 1 hour at 37uC in an atmosphere of 5% CO2.
After incubation, cells were washed three times with Hank’s
balanced salt solution to remove non-adherent cells, and
equilibrated with Dulbecco’s modified Eagle’s medium that
contained 10% fetal bovine serum. Cells were allowed to rest for
24 h before treatment with LPS.
Western blot
Peritoneal macrophages isolated from mice treated with
laquinimod or vehicle were stimulated with LPS (1 mg/ml) for
various time points. Cell pellets were treated with ice-cold lysis
buffer (50 mM Tris-HCl, pH 7.4, 1% NP-40, 0.25% sodium
deoxycholate, 150 mM NaCl, 1 mM EDTA, 1 mM phenyl-
methylsulfonylfluoride (PMSF), 1 mM Na3VO4, 1 mM NaF)
containing protease inhibitors and phosphatase inhibitors (Roche).
Proteins were separated by SDS-PAGE and transferred onto
nitrocellulose membranes (Amersham Biosciences) for subsequent
immunoblotting with antibodies specific for phosphorylated
STAT1, pan-STAT1, phosphorylated p38MAPK and p38 MAPK
(Cell Signaling Technology, Danvers, MA).
Flow cytometry
Single-cell suspensions were incubated with anti-CD16/CD32
(1:100) to prevent nonspecific antibody binding, then stained with
anti-CD4, -CD8, -CD62L, -CD44, -CD11c, -CD11b, -B220, Gr1
(Ly6C/G), -CD3, -MHCII, -CD40, -PDL-1, -CD80, and -CD86
(all 1:100) (eBioscience, San Diego, CA). Intracellular cytokine
production by CD4+ T cells and APC was analyzed by monitoring
the expression of IFN-c, IL-17, GM-CSF, IL-6, IL-12/23 (p40),
TNF and IL-10 (1:100) (eBioscience). Foxp3 staining was
performed according to the manufacturer’s protocol (eBioscience).
For intracellular cytokine staining, T cells were stimulated with
phorbol 12-myristate 13-acetate (PMA, 50 ng/ml) plus ionomycin
(500 ng/ml) in the presence of GolgiStop (1 ml/ml) (BD, San Jose,
CA). CD11b+ cells were stimulated with LPS (1 mg/ml) for 12 h in
the presence of GolgiStop. Cells were analyzed by flow cytometry
on a FACS Canto (BD).
Statistical analysis
Data are shown as mean 6 s.e.m or s.d. We examined
significance between groups using the Mann-Whitney U test. A
value of P#0.05 was considered significant.
Supporting Information
Figure S1 Splenocytes and lymph node cells were
isolated from PLP-immunized mice treated with laqui-
nimod or vehicle for 10 days. Cells were restimulated in vitro
and analyzed by FACS for secretion of IFN-c, IL-17, GM-CSF
and expression of CD25 and Foxp3 by CD4+ cells at the day of
transfer into naı¨ve SJL/J recipients. Data are representative of two
independent experiments.
(TIF)
Figure S2 Splenic purified CD11b+ cells from laquini-
mod- or vehicle-treated mice were used as APC in co-
culture with untreated naive CD4+ 2D2 T cells. Converse-
ly, naive 2D2 T cells were isolated from laquinimod- or vehicle-
treated 2D2 mice and cultured with purified vehicle treated
CD11b+ cells and Ag (MOG p35-55). Proliferative response of
2D2 cells is displayed as counts per minute (cpm) after [3H]-
thymidine incorporation. Results are shown as means of triplicates
6 s.e.m. Data are representative of three independent experi-
ments.
(TIF)
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Figure S3 DC were isolated from the spleen and defined
as CD11chigh CD8+ cDC (CD11b2CD42). Relative percent-
ages of CD8+ DC and total splenic CD8+ T cells from laquinimod-
treated compared to control mice is shown (n = 4). Results are
shown as means 6 s.e.m. Data are representative of two
independent experiments.
(TIF)
Figure S4 Laquinimod modulates cytokine profiles of
CD11b+CD11c2 and CD11c+ cells. FACS analysis of
cytokines produced by CD11b+CD11c2 and CD11c+ cells isolated
from spleen of mice on day 11 after immunization with MOG
p35-55 and treated with laquinimod or vehicle. Shown are TNF,
IL12/IL23p40, IL-6 and IL-10. Data are representative of two
independent experiments.
(TIF)
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